Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) | EUROPEAN JOURNAL OF CANCER |